Pfizer Inc. (NYSE: PFE), the New York-based pharmaceutical company, announced on October 14, 2026, that it will present 57 company-sponsored, investigator-sponsored and collaborative research abstracts at IDWeek 2026, taking place October 21 through October 24 in Washington, DC. The scientific programme includes 12 oral presentations addressing investigational vaccines, established immunization products and infectious disease treatments. Major subjects include its Phase 3 Lyme disease vaccine candidate developed with Valneva, a next-generation 25-valent pneumococcal conjugate vaccine and new evidence involving respiratory syncytial virus prevention.
The conference will provide a more detailed examination of several programmes for which Pfizer has already disclosed important findings. Its investigational six-valent Lyme vaccine demonstrated 73.2% efficacy in one prespecified Phase 3 analysis, but the confidence interval failed to satisfy the trial’s primary statistical success criterion. Separately, Pfizer’s 25-valent pediatric pneumococcal vaccine produced stronger immunogenicity against serotype 3 than PREVNAR 20 in Phase 2 testing and has progressed into a pivotal Phase 3 programme.
Pfizer will also present real-world evidence concerning ABRYSVO, including protection against RSV hospitalization among infants following maternal vaccination and vaccination effectiveness among nursing home residents across three RSV seasons. Additional investigations cover updated COVID-19 vaccination, antiviral treatment and meningococcal protection. These studies differ substantially in maturity and evidentiary strength, making it important to separate completed efficacy findings from upcoming analyses and scientific presentations.
The programme reinforces Pfizer’s investment in infectious disease prevention as vaccine manufacturers face changing demand, public health recommendations and competition. However, conference participation does not itself represent a regulatory approval or confirm that every investigational product will succeed. The significance of the findings will depend on how well they address unresolved clinical questions and support future regulatory decisions.
Why is Pfizer’s Phase 3 Lyme disease vaccine a major focus at IDWeek?
Pfizer and Valneva are developing PF-07307405, also known as LB6V and formerly VLA15, as an investigational vaccine against Lyme disease. The candidate targets six variants of outer surface protein A, or OspA, associated with Borrelia bacteria transmitted through infected ticks. It is intended to generate antibodies capable of interfering with bacterial transmission during tick feeding.
The pivotal VALOR study, registered as NCT05477524, evaluated the vaccine in people aged five years and older living in Lyme-endemic regions of North America and Europe. The trial used a randomized, placebo-controlled design to assess prevention of confirmed Lyme disease. Pfizer and Valneva announced topline results on March 23, 2026, reporting efficacy above 70% in their prespecified analyses.
One analysis measured protection beginning 28 days after the fourth vaccine dose and showed efficacy of 73.2%, with a 95% confidence interval of 15.8% to 93.5%. A second prespecified analysis, beginning one day after the fourth dose, showed efficacy of 74.8%, with a 95% confidence interval of 21.7% to 93.9%. Both estimates indicated fewer confirmed infections among vaccine recipients than placebo recipients.
However, the trial’s primary statistical success requirement specified that the lower confidence interval bound must exceed 20%. The first analysis did not meet that threshold because its lower bound was 15.8%. The second analysis did satisfy the corresponding numerical criterion, creating a more complicated regulatory interpretation than the headline efficacy percentage alone suggests.
Pfizer and Valneva attributed the statistical uncertainty partly to fewer confirmed Lyme disease cases than anticipated during the study. The lower event count widened the confidence intervals around the efficacy estimates. The detailed Phase 3 presentation at IDWeek on October 22 will therefore be particularly relevant for understanding the trial’s results, including the differences between the two analysis windows.
What does the European regulatory review mean for the Lyme vaccine?
The European Medicines Agency began reviewing the marketing authorization application for LB6V in August 2026. This represents a regulatory submission milestone rather than approval of the vaccine. The agency must determine whether the complete evidence package provides an acceptable balance of demonstrated protection, safety and remaining uncertainty.
The candidate could address an important unmet need because there is currently no licensed human Lyme disease vaccine available in the United States or European Union. Lyme disease can cause fever, rash and other early symptoms, with untreated infections sometimes leading to neurological, cardiac or joint complications. Prevention currently relies substantially on reducing exposure to infected ticks and recognizing possible infections promptly.
Pfizer and Valneva reported no new safety concerns in the topline Phase 3 analysis. Nevertheless, regulatory review requires assessment of the full safety database, including potential adverse reactions across different age groups. Long-term protection and the durability of immune responses are additional questions relevant to vaccination schedules.
The vaccine’s proposed commercial opportunity depends on more than regulatory authorization. Uptake may vary according to geography, seasonal tick exposure, public health recommendations and the willingness of individuals to complete the required vaccination schedule. The final indication and dosing instructions will be established through regulatory decisions.
The IDWeek presentation provides an opportunity for more detailed discussion of the VALOR evidence before those decisions. It does not remove the statistical limitation affecting the trial’s primary analysis, which remains central to evaluating the programme.
How could Pfizer’s 25-valent pneumococcal vaccine improve on PREVNAR 20?
Pfizer’s investigational PF-07872412 is a 25-valent pneumococcal conjugate vaccine designed to provide protection against five more serotypes than PREVNAR 20. The company is developing the candidate primarily for pediatric use, where pneumococcal infections can cause invasive disease, pneumonia and other serious complications. Expanding serotype coverage may help address disease caused by bacterial variants not included in existing vaccines.
The company announced positive Phase 2 findings on May 20, 2026. In that study, healthy infants receiving the 25-valent candidate showed immune responses across the included serotypes, with particularly strong responses against serotype 3. Pfizer reported approximately ninefold to fifteenfold greater serotype 3 immunogenicity responses after the third and fourth doses compared with PREVNAR 20.
Serotype 3 remains an important concern because it contributes to invasive pneumococcal disease and complicated pneumonia despite existing vaccination programmes. A stronger immune response may support improved protection, but immunogenicity measurements are not identical to demonstrated reductions in clinical disease. The relationship between antibody levels and protective effectiveness requires appropriate evaluation.
Pfizer estimates that the candidate could potentially cover serotypes responsible for approximately 90% of pneumococcal disease in United States children. This is a coverage estimate based on disease-causing serotypes rather than a demonstrated 90% vaccine efficacy result. The actual protection achieved will depend on immune responses, circulating bacterial strains and real-world vaccination outcomes.
The Phase 2 programme supported progression into pediatric Phase 3 testing, which began in May 2026. The pivotal programme is evaluating immunogenicity, safety and tolerability using a schedule involving vaccination at two, four and six months, followed by a booster at approximately 12 to 15 months. Pfizer plans to present further Phase 2 details at IDWeek on October 24.
What can the Phase 3 pediatric pneumococcal programme establish?
The Phase 3 studies compare the new vaccine against PREVNAR 20 in healthy infants and children. They are designed to determine whether the candidate produces appropriate immune responses while maintaining an acceptable safety profile. The programme includes plans to evaluate up to approximately 2,400 participants in its pivotal studies.
For a conjugate vaccine, immune responses against individual serotypes are especially important because protection can vary across bacterial variants. Adding serotypes increases the intended coverage but also creates a need to demonstrate that immune responses to the existing components remain adequate. Researchers must therefore assess the full serotype-specific profile rather than relying on the total number of components.
The Phase 2 study reported a tolerability profile broadly consistent with the approved comparator, including expected injection-site reactions such as pain, redness and swelling. However, larger trials provide more information about adverse-event frequency and the consistency of responses across participant groups. They also support evaluation of the proposed schedule before any regulatory submission.
The Phase 3 programme does not automatically establish that the 25-valent candidate prevents more infections than PREVNAR 20 in routine clinical practice. That conclusion would require appropriate clinical or post-authorization evidence. Nevertheless, improved serotype coverage and strong immunogenicity may provide a rationale for future vaccination policy discussions.
Pfizer is also pursuing a separate 35-valent pneumococcal candidate for adults. The pediatric 25-valent programme and adult 35-valent research involve distinct development strategies, meaning their formulations and regulatory paths should not be treated as interchangeable.
What did Australia’s STREETON study show about maternal RSV vaccination?
One of Pfizer’s important real-world presentations concerns the STREETON study, which evaluated maternal RSV vaccination in Australia after the introduction of a national immunization programme. The investigation was published in JAMA Pediatrics in August 2026 and involved 1,012 hospitalized infants aged six months or younger. It used a test-negative case-control design across nine Australian hospitals.
The study estimated that maternal vaccination with the bivalent RSV prefusion F vaccine was associated with 77.8% effectiveness against hospitalization for RSV lower respiratory tract disease among infants from birth through six months of age. The 95% confidence interval ranged from 66.4% to 85.3%. For severe RSV lower respiratory tract disease hospitalization, estimated effectiveness was 80.4%.
Protection was particularly strong in the earliest months of life. Estimated vaccine effectiveness reached 86.3% among infants from birth through two months of age and 80.2% through three months. These results are clinically relevant because very young infants face a substantial burden from severe RSV infection.
The study also reported broadly consistent effectiveness across RSV-A and RSV-B subtypes and several vaccination-related characteristics. However, it was observational rather than a newly randomized efficacy trial. Researchers used statistical methods to address differences between vaccinated and unvaccinated groups, but residual confounding remains possible.
The IDWeek presentation on October 24 will provide another opportunity to examine these findings. They support the real-world benefit of maternal RSV vaccination under Australia’s programme, but vaccine administration must continue to follow the applicable recommendations and approved schedules in each country.
Why is Pfizer evaluating RSV effectiveness across three nursing home seasons?
Pfizer is also presenting a retrospective study of ABRYSVO effectiveness among United States Department of Veterans Affairs nursing home residents. The analysis examines laboratory-confirmed RSV infection across three respiratory virus seasons, including the 2025-2026 period. It is intended to provide information about the persistence of protection in a population at increased risk of serious respiratory disease.
Older adults living in long-term care facilities may have multiple medical conditions and increased vulnerability to respiratory infections. Vaccine effectiveness in these settings can differ from results obtained in healthier populations during randomized clinical trials. Real-world follow-up is therefore important for understanding protection over time.
The three-season analysis is particularly relevant because immunity may change as time passes after vaccination. Researchers need to distinguish waning protection from differences in circulating virus activity, infection testing and characteristics of the population observed during each season. A retrospective design introduces additional limitations involving data completeness and confounding.
Pfizer’s October announcement does not provide the numerical third-season vaccine effectiveness estimate. It would therefore be premature to state that ABRYSVO retains a particular percentage of protection after three seasons. The forthcoming presentation should be evaluated according to its actual population, outcome definitions and statistical adjustments.
Evidence of sustained protection could inform discussions about revaccination strategies. However, observational effectiveness findings do not independently establish a new dosing recommendation or authorize repeated vaccination outside applicable guidance.
What other COVID-19 and meningococcal findings will Pfizer present?
Pfizer and BioNTech will present Phase 3 safety and immunogenicity findings for the LP.8.1-adapted formulation of COMIRNATY in children aged five to 11 years with medical conditions increasing their risk of severe COVID-19. The study evaluated a single 10-microgram dose of the 2025-2026 formulation. The announcement describes supportive immune responses and safety findings but does not disclose complete numerical results.
The company will also present an analysis concerning extended-duration PAXLOVID treatment in severely immunocompromised adults with COVID-19. The presentation focuses on virologic control, an important issue because some patients with impaired immune function may experience prolonged viral replication. However, the October announcement does not provide the complete trial results or establish a new approved PAXLOVID treatment duration.
Another presentation will examine longer-term protection following PENBRAYA, Pfizer’s pentavalent meningococcal vaccine. The analysis uses modeling to investigate whether antibodies against meningococcal group B strains may persist for up to five years. A modeled prediction of antibody persistence should not be confused with directly observed five-year clinical protection against meningococcal disease.
Together, these investigations demonstrate the breadth of Pfizer’s infectious disease programme, but their implications differ. Randomized vaccine studies, observational effectiveness analyses and modeled estimates provide different levels and types of evidence. Clinical and regulatory conclusions must preserve those distinctions.
What will determine the commercial significance of Pfizer’s IDWeek 2026 programme?
Pfizer is managing an infectious disease portfolio spanning established products and investigational vaccines. Commercial growth depends partly on maintaining confidence in existing products while introducing innovations addressing remaining gaps in protection. The upcoming presentations cover both objectives, with ABRYSVO and PREVNAR 20 representing established franchises and LB6V and the 25-valent vaccine representing future opportunities.
The Lyme disease programme faces an especially important regulatory decision because the primary Phase 3 analysis did not satisfy its prespecified statistical threshold. The second analysis provides encouraging evidence, but approval remains uncertain. Detailed clinical findings and regulators’ interpretation of the complete package will determine the next stage.
The pediatric pneumococcal programme addresses a different challenge. Pfizer already markets a major vaccine in the category, so a successor candidate must demonstrate appropriate immunogenicity and safety while offering a credible rationale for expanded coverage. Greater serotype breadth alone does not establish superior real-world effectiveness.
The RSV studies may help strengthen the evidence supporting existing vaccination strategies, particularly for infants and older adults. However, real-world effectiveness estimates do not automatically translate into higher sales, changes in national recommendations or new authorized schedules.
Pfizer’s IDWeek 2026 programme brings together substantial clinical and epidemiological evidence, but the most consequential developments remain ahead. Regulatory decisions on the Lyme vaccine, completion of the pediatric 25-valent Phase 3 programme and further analysis of RSV protection will determine whether the research generates meaningful changes in prevention and treatment. The 57-abstract programme demonstrates the scale of Pfizer’s work, while the quality and interpretation of individual results will determine its medical and commercial impact.
